文献速递核素与放射性配体治疗肿瘤 PET/CT

基于体素的剂量学可预测结直肠癌肝转移90Y放射性肝段切除术后局部肿瘤进展

Voxel-Based Dosimetry Predicts Local Tumor Progression Post 90 Y Radiation Segmentectomy of Colorectal Liver Metastases.
PubMed 文献 · Clin Nucl Med · 2025-01-01

这项单中心回顾性研究纳入2015至2023年接受放射性肝段切除(处方肿瘤剂量>190 Gy)的结直肠癌肝转移患者36例、38次操作、57个肿瘤,评估剂量学与局部肿瘤进展的关系。中位总生存期14.3个月,肿瘤平均剂量≥400 Gy且5 mm边缘平均吸收剂量≥350 Gy者1年无局部进展生存率为83.3%,多因素分析显示两者为独立预测因素(HR 0.11)。

要点

  • 肿瘤平均剂量≥400 Gy者1年无局部进展生存率68.6%,未达该阈值者为14.3%(P=0.013)。
  • 肿瘤平均剂量≥400 Gy且5 mm边缘平均吸收剂量≥350 Gy者1年无局部进展生存率83.3%(P=0.006)。
  • 肿瘤立体定向照射≥300 Gy(至少95%肿瘤体积接受≥300 Gy)时未观察到局部进展。

核心结论

  • 肿瘤平均剂量≥400 Gy、边缘平均吸收剂量≥350 Gy及立体定向肿瘤照射≥300 Gy与放射性肝段切除术后无局部进展生存期延长相关。

研究设计与样本

  • 单中心回顾性研究,2015至2023年接受放射性肝段切除(处方肿瘤剂量>190 Gy)的结直肠癌肝转移患者36例,共38次操作、57个肿瘤。
  • 肿瘤及边缘剂量由SPECT/CT和PET/CT图像计算,疗效和局部肿瘤进展采用RECIST 1.1和PERCIST标准评估。
  • 无局部进展生存期和总生存期采用Kaplan-Meier法估计,预测因素采用Cox比例风险模型评估。

主要发现

  • 放射性肝段切除术后中位总生存期为14.3个月(95%CI:10.8-30.7)。
  • 影像学完全缓解(HR:1.29e-16,95%CI:4.06e-17-4.07e-16,P<0.001)和代谢完全缓解(HR:0.38,95%CI:0.15-0.95,P=0.038)与无局部进展生存期延长相关。
  • 接受肿瘤平均剂量≥400 Gy且5 mm周围边缘平均吸收剂量≥350 Gy的肿瘤1年无局部进展生存率为83.3%(P=0.006)。
  • 接受肿瘤平均剂量≥400 Gy的肿瘤1年无局部进展生存率为68.6%,未达该阈值者为14.3%(P=0.013)。
  • 多因素分析中,肿瘤平均剂量≥400 Gy和5 mm边缘平均吸收剂量≥350 Gy是无局部进展生存期的独立预测因素(HR:0.11;95%CI:0.01-0.81;P=0.03)。

关键数值与推荐

  • 放射性肝段切除的处方肿瘤剂量>190 Gy。
  • 肿瘤平均剂量≥400 Gy且5 mm周围边缘平均吸收剂量≥350 Gy的肿瘤1年无局部进展生存率为83.3%(P=0.006)。
  • 肿瘤平均剂量≥400 Gy的肿瘤1年无局部进展生存率为68.6%,未达该阈值者为14.3%(P=0.013)。
  • 肿瘤立体定向照射≥300 Gy(至少95%肿瘤体积接受≥300 Gy)时未观察到局部进展。
  • 多因素分析中肿瘤平均剂量≥400 Gy和5 mm边缘平均吸收剂量≥350 Gy的HR为0.11(95%CI:0.01-0.81;P=0.03)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiation segmentectomy (RS) is an alternative potential local curative treatment for selected colorectal liver metastases (CLMs) not amenable to ablation or limited resection. PURPOSE: The aim of this study was to evaluate the dosimetric response of low volume CLMs to RS in heavily pretreated patients who are not candidates for resection or percutaneous ablation. PATIENTS AND METHODS: This single-center retrospective study evaluated CLMs patients treated with RS (prescribed tumor dose >190 Gy) from 2015 to 2023. RS doses to tumor(s) and margins were calculated from SPECT/CT and PET/CT images. Response and local tumor progression (LTP) were assessed using anatomic (RECIST 1.1) and metabolic (PERCIST) criteria. LTP-free survival (LTPFS) and overall survival were estimated with Kaplan-Meier methodology. Variables were assessed as predictors of LTPFS using the Cox proportional hazards model. RESULTS: Thirty-six patients underwent 38 RS procedures to treat 57 tumors. Median time from initial diagnosis to detection of liver metastases and RS were 16.4 (interquartile range: 6.5-32.2) and 26.8 (interquartile range: 12.5-40.0) months, respectively. Median overall survival after RS was 14.3 (95% confidence interval [CI]: 10.8-30.7) months. Predictors of LTPFS included tumor number(s), mean tumor dose (MTD), and margin mean absorbed dose (MMAD). Complete radiographic (hazards ratio [HR]: 1.29e-16, 95% CI: 4.06e-17-4.07e-16, P < 0.001) and metabolic response (HR: 0.38, 95% CI: 0.15-0.95, P = 0.038) correlated with prolonged LTPFS. One-year LTPFS rate was 83.3% for tumors receiving MTD ≥400 Gy and a 5-mm surrounding MMAD ≥350 Gy ( P = 0.006). No instances of LTP were observed when tumors received stereotactic irradiation over 300 Gy (at least 95% of the tumor volume received ≥300 Gy). One-year LTPFS rate for tumors receiving MTD ≥400 Gy was 68.6% versus 14.3% for those that did not reach this threshold ( P = 0.013). In multivariate analysis, MTD ≥400 Gy and 5-mm MMAD ≥350 Gy were independent predictors of LTPFS (HR: 0.11; 95% CI: 0.01-0.81; P = 0.03). CONCLUSIONS: MTD ≥400 Gy, MMAD ≥350 Gy, and stereotactic tumor irradiation ≥300 Gy are associated with prolonged LTPFS after RS for CLMs.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Dimopoulos PM, Sotirchos VS, Dunne-Jaffe C, et al. Voxel-Based Dosimetry Predicts Local Tumor Progression Post 90 Y Radiation Segmentectomy of Colorectal Liver Metastases. Clin Nucl Med. 2025. PMID: 39745670. doi:10.1097/RLU.0000000000005565

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。